Abstract 153P
Background
T cell immunoglobulin and mucin domain molecule 3 (Tim-3) is of overexpression in immunotherapy-resistant tumors. This single-arm, two-cohort, phase 2 study (NCT05563480) aimed to explore the efficacy and safety of TQB2618, a novel monoclonal antibody agent blockading Tim-3, plus PD-1 blockade penpulimab in subsequent-line treatment (cohort 1) of immunotherapy-resistant R/M NPC or in the first line by incorporating into chemotherapy (cohort 2) in treatment-naïve R/M NPC. Here, we report the preliminary results of cohort 1.
Methods
Eligible pts were diagnosed with histologically confirmed R/M NPC with ≥ 1 measurable lesion and had progressed on or after ≥ 1 line of platinum-based chemotherapy and PD-(L)1 immunotherapy. Pts were given penpulimab 200 mg and TQB2618 intravenously once per 3 weeks till disease progression or intolerance. Two TQB2618 dose levels of 1200 mg and 1500 mg were escalated initially according to the 3+3 design in a safety lead-in phase to determine the recommended dose in expansion phase. The primary aim of cohort 1 is to determine dose limiting toxicity (DLT) and tumor response.
Results
Between November 2022 and September 2023, 17 pts were enrolled (median [range] age, 49 [33–62] years; 41.2% women). The median previous treatment lines were 2 (range: 1–5). All pts developed metastasis and 7 (41.2%) were found liver lesions. The DLT was not observed, and 1500 mg was recommended for TQB2618. All pts received safety evaluation and 13 (76.5%) occurred at least one AE. The most common AEs were hypothyroidism (41.2%) and increased aspartate aminotransferase (23.5%). AEs of ≥ grade 3 or serious AEs were not observed. Seven pts had target lesions shrink although no one reached partial response. Nine pts obtained stable disease lasting for at least 4 weeks, given a disease control rate of 52.9%. The median PFS was 1.6 mo (95% CI, 0.0–3.2); 3 mo- and 6 mo-PFS was 27.3% and 18.2%, respectively. One pt was still on treatment after a follow-up for 14 months.
Conclusions
This novel dual-drug immunotherapy showed favorable safety profile, but the activity was limited in immunotherapy-resistant R/M NPC.
Clinical trial identification
NCT05563480.
Legal entity responsible for the study
The authors.
Funding
Chia Tai TianQing Pharmaceutical Group Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
31P - Peripheral-blood Immune-predictors of pathological complete response in patients with triple-negative breast cancer undergoing neoadjuvant chemo-immunotherapy
Presenter: Celeste Santoro
Session: Poster Display session
Resources:
Abstract
32P - Immune T cell subsets dynamics in the early TNBC treatment setting
Presenter: Rocío Martín Lozano
Session: Poster Display session
Resources:
Abstract
33P - Tumor-specific CD4 Th1 responses in long-term responder melanoma patients treated with immune checkpoint inhibitors.
Presenter: Jessica Mathiot
Session: Poster Display session
Resources:
Abstract
34P - Linking early immunity changes to clinical outcomes in cutaneous squamous cell carcinoma following anti-programmed death cell-1 (PD-1) treatment
Presenter: Marcella Scala
Session: Poster Display session
Resources:
Abstract
36P - Exploring the role of soluble B7-H3 (sB7-H3) as a biomarker to predict the clinical benefit and/or the occurrence of immune related adverse events (irAEs) in advanced cancer patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Luigi Liguori
Session: Poster Display session
Resources:
Abstract
37P - Lymphocyte Subpopulation Balances as a Blood Biomarker for Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
Presenter: Mireille Langouo fontsa
Session: Poster Display session
Resources:
Abstract
38P - Biomarkers predictive of response to immune checkpoint inhibitor therapy in patients with metastatic melanoma
Presenter: Eliza Bob
Session: Poster Display session
Resources:
Abstract
39P - Analysis of the immune response patterns in localized prostate cancer
Presenter: Sara Merler
Session: Poster Display session
Resources:
Abstract
40P - MANIFEST: A Multiomic Profiling Platform for Immuno-Oncology Biomarker Discovery
Presenter: Zayd Tippu
Session: Poster Display session
Resources:
Abstract
41P - Total tumor burden and radiomics to evaluate response in dose escalation studies: Roginolisib (IOA-244), a highly selective PI3Kd inhibitor in metastatic uveal melanoma patients
Presenter: Anna Di Giacomo
Session: Poster Display session
Resources:
Abstract